Radiopharm Theranostics Ltd (RADX) Operating Expenses (2023 - 2026)

Radiopharm Theranostics (RADX) has reported Operating Expenses for 4 consecutive years, with $618649.7 the latest figure, recorded in Q2 2026.

• On a quarterly basis, Operating Expenses rose 101.47% year-over-year to $618649.7 in Q2 2026; TTM through Jun 2026 was -$76.1 million, a N/A change from a year earlier, with the FY2026 full-year figure at $2.9 million, up 106.99% from the prior year.
• Operating Expenses was $618649.7 for Q2 2026 at Radiopharm Theranostics, up from -$42.1 million in the prior quarter.
• Over five years, Operating Expenses peaked at $618649.7 in Q2 2026 and troughed at -$42.1 million in Q2 2025.
• A 4-year average of -$19.0 million and a median of -$17.3 million in 2023 frame the typical range for Operating Expenses.
• Across the five-year window, Operating Expenses slumped 14795.41% in 2025 and surged 101.47% in 2026, its largest moves.
• Over 4 years, Operating Expenses stood at -$34.9 million in 2023, then surged by 100.82% to $286814.0 in 2024, then tumbled by 14795.41% to -$42.1 million in 2025, then surged by 101.47% to $618649.7 in 2026.
• The last three Operating Expenses figures came in at $618649.7 (Q2 2026), -$42.1 million (Q2 2025), and $286814.0 (Q2 2024), per Business Quant data.